MetaVia's DA-1726 cuts liver fat 68% versus placebo in interim Phase 1 data
Bitget2026/11/05 13:56- MetaVia reported positive interim Phase 1 results for DA-1726, showing significant liver fat reduction, weight loss and improved blood sugar control.
- Results were presented November 4, 2026, at the Precision Liver Symposium, covering otherwise healthy adults with obesity treated for 16 weeks.
- One serious vomiting event was considered possibly treatment-related; the participant recovered, with no gastrointestinal events causing study discontinuation.
- A 48-week Phase 2 trial targeting up to 150 patients with metabolic dysfunction-associated and alcohol-associated liver disease is planned for second-half 2027.
- Full Phase 1 Part 3A and Part 3B data are expected in the first quarter of 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Layer 33 calls for a pause on removing validators under the new Solana Foundation regulations
HIVE’s Bitcoin output jumps 49%, but mining revenue still falls
Asia-Pacific stock markets follow the overnight rally in US tech stocks, with South Korea's KOSPI up 5% at the open, SK Hynix surging more than 7%, and Nikkei 225 rising over 2%.
This round of rebound occurred after the market experienced severe turbulence. Last week, concerns over the potential for stricter regulation of the artificial intelligence industry, due to the US Congressional election results, triggered a large-scale sell-off in chip stocks. Several market participants believe that this rebound indicates investors have not abandoned the AI trading narrative, and last week’s sell-off was more about position adjustments rather than a trend reversal.
Barrick’s Marquee gold project faces hazy study timing
Crypto prices
More
